| 000 | 02753 a2200757 4500 | ||
|---|---|---|---|
| 005 | 20250517034412.0 | ||
| 264 | 0 | _c20150928 | |
| 008 | 201509s 0 0 eng d | ||
| 022 | _a1474-5488 | ||
| 024 | 7 |
_a10.1016/S1470-2045(15)00021-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aThatcher, Nick | |
| 245 | 0 | 0 |
_aNecitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. _h[electronic resource] |
| 260 |
_bThe Lancet. Oncology _cJul 2015 |
||
| 300 |
_a763-74 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 |
_aCarcinoma, Squamous Cell _xdrug therapy |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGentamicins _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasm Invasiveness _xpathology |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aSex Factors |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aHirsch, Fred R | |
| 700 | 1 | _aLuft, Alexander V | |
| 700 | 1 | _aSzczesna, Aleksandra | |
| 700 | 1 | _aCiuleanu, Tudor E | |
| 700 | 1 | _aDediu, Mircea | |
| 700 | 1 | _aRamlau, Rodryg | |
| 700 | 1 | _aGaliulin, Rinat K | |
| 700 | 1 | _aBálint, Beatrix | |
| 700 | 1 | _aLosonczy, György | |
| 700 | 1 | _aKazarnowicz, Andrzej | |
| 700 | 1 | _aPark, Keunchil | |
| 700 | 1 | _aSchumann, Christian | |
| 700 | 1 | _aReck, Martin | |
| 700 | 1 | _aDepenbrock, Henrik | |
| 700 | 1 | _aNanda, Shivani | |
| 700 | 1 | _aKruljac-Letunic, Anamarija | |
| 700 | 1 | _aKurek, Raffael | |
| 700 | 1 | _aPaz-Ares, Luis | |
| 700 | 1 | _aSocinski, Mark A | |
| 773 | 0 |
_tThe Lancet. Oncology _gvol. 16 _gno. 7 _gp. 763-74 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S1470-2045(15)00021-2 _zAvailable from publisher's website |
| 999 |
_c24953711 _d24953711 |
||